Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that MYQORZO® (aficamten) has been approved by the China National ...

In a decades-long effort, researchers have discovered how to tweak the molecular pathways that turn heart muscle motors up or ...

The AHA is expanding its initiative to improve detection, standardize care, and enhance treatment for hypertrophic cardiomyopathy.

The European Medicines Agency (EMA)’s Committee for Medicinal Products for Human Use (CHMP) has recommended granting ...

Final Decision from European Commission Expected in Q1 2026 SOUTH SAN FRANCISCO, Calif., Dec. 12, 2025 (GLOBE NEWSWIRE) -- ...

US biotech Cytokinetics (Nasdaq: CYTK) has secured the first global approval for its cardiac myosin inhibitor aficamten, ...

Feline HCM remains a complex, prevalent, and often-devastating disease. While cats can remain asymptomatic for years, progression to CHF or thromboembolism can be sudden. A structured approach to ...

Background Dyspnoea and reduced exercise capacity are common features in hypertrophic cardiomyopathy (HCM) without left ...

The gene therapies for cardiomyopathies market is poised for strong growth as advancements in genomic medicine accelerate the ...

Final Decision from European Commission Expected in Q1 2026 SOUTH SAN FRANCISCO, Calif., Dec. 12, 2025 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that the Committee ...

Some lawn chemicals increase the risk of cancer, so don’t use them, or keep your dog off the grass until the application ...

When it comes to Cobenfy’s indication, the FDA objected to the suggestion in the ad that the drug has efficacy in ...